nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Vincristine—sarcoma	0.137	0.172	CbGbCtD
Canagliflozin—ABCC2—Etoposide—sarcoma	0.125	0.158	CbGbCtD
Canagliflozin—CYP3A4—Thiotepa—sarcoma	0.0903	0.114	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—sarcoma	0.0855	0.108	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—sarcoma	0.0724	0.0911	CbGbCtD
Canagliflozin—ABCB1—Mitoxantrone—sarcoma	0.0648	0.0815	CbGbCtD
Canagliflozin—ABCB1—Vincristine—sarcoma	0.0446	0.0561	CbGbCtD
Canagliflozin—ABCB1—Etoposide—sarcoma	0.0408	0.0514	CbGbCtD
Canagliflozin—CYP3A4—Mitoxantrone—sarcoma	0.0388	0.0488	CbGbCtD
Canagliflozin—UGT2B4—pericardium—sarcoma	0.0314	0.384	CbGeAlD
Canagliflozin—ABCB1—Doxorubicin—sarcoma	0.0279	0.035	CbGbCtD
Canagliflozin—CYP3A4—Vincristine—sarcoma	0.0267	0.0336	CbGbCtD
Canagliflozin—CYP3A4—Etoposide—sarcoma	0.0245	0.0308	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—sarcoma	0.0167	0.021	CbGbCtD
Canagliflozin—SLC5A1—mammary gland—sarcoma	0.00973	0.119	CbGeAlD
Canagliflozin—SLC5A1—cardiac atrium—sarcoma	0.0045	0.0551	CbGeAlD
Canagliflozin—SLC5A2—testis—sarcoma	0.00429	0.0525	CbGeAlD
Canagliflozin—UGT2B4—cardiac atrium—sarcoma	0.00415	0.0508	CbGeAlD
Canagliflozin—SLC5A1—testis—sarcoma	0.00325	0.0398	CbGeAlD
Canagliflozin—UGT2B4—liver—sarcoma	0.00283	0.0346	CbGeAlD
Canagliflozin—ALB—mammary gland—sarcoma	0.00283	0.0346	CbGeAlD
Canagliflozin—Serum creatinine increased—Mitoxantrone—sarcoma	0.00262	0.0212	CcSEcCtD
Canagliflozin—Rash papular—Epirubicin—sarcoma	0.00202	0.0163	CcSEcCtD
Canagliflozin—ORM1—hematopoietic system—sarcoma	0.00196	0.024	CbGeAlD
Canagliflozin—UGT1A9—liver—sarcoma	0.00193	0.0237	CbGeAlD
Canagliflozin—Rash papular—Doxorubicin—sarcoma	0.00186	0.0151	CcSEcCtD
Canagliflozin—Cystitis noninfective—Thiotepa—sarcoma	0.00182	0.0148	CcSEcCtD
Canagliflozin—Cystitis—Thiotepa—sarcoma	0.0018	0.0146	CcSEcCtD
Canagliflozin—Blood urea increased—Thiotepa—sarcoma	0.00176	0.0143	CcSEcCtD
Canagliflozin—Bladder pain—Thiotepa—sarcoma	0.00169	0.0137	CcSEcCtD
Canagliflozin—Hyperkalaemia—Mitoxantrone—sarcoma	0.00158	0.0128	CcSEcCtD
Canagliflozin—Blood urea increased—Mitoxantrone—sarcoma	0.00152	0.0123	CcSEcCtD
Canagliflozin—Urine output increased—Vincristine—sarcoma	0.00149	0.0121	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Epirubicin—sarcoma	0.00143	0.0116	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Epirubicin—sarcoma	0.00137	0.0111	CcSEcCtD
Canagliflozin—Polyuria—Vincristine—sarcoma	0.00137	0.0111	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Doxorubicin—sarcoma	0.00132	0.0107	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Doxorubicin—sarcoma	0.00127	0.0103	CcSEcCtD
Canagliflozin—Blood creatinine increased—Thiotepa—sarcoma	0.00127	0.0103	CcSEcCtD
Canagliflozin—Renal failure acute—Mitoxantrone—sarcoma	0.00127	0.0103	CcSEcCtD
Canagliflozin—ORM1—bone marrow—sarcoma	0.00126	0.0154	CbGeAlD
Canagliflozin—Dehydration—Thiotepa—sarcoma	0.00126	0.0102	CcSEcCtD
Canagliflozin—Serum creatinine increased—Epirubicin—sarcoma	0.00122	0.00989	CcSEcCtD
Canagliflozin—Rash maculo-papular—Etoposide—sarcoma	0.00122	0.00986	CcSEcCtD
Canagliflozin—Serum creatinine increased—Doxorubicin—sarcoma	0.00113	0.00915	CcSEcCtD
Canagliflozin—Dehydration—Vincristine—sarcoma	0.00112	0.00904	CcSEcCtD
Canagliflozin—Blood creatinine increased—Mitoxantrone—sarcoma	0.00109	0.00887	CcSEcCtD
Canagliflozin—Dehydration—Mitoxantrone—sarcoma	0.00109	0.00881	CcSEcCtD
Canagliflozin—ABCC2—tendon—sarcoma	0.00107	0.0131	CbGeAlD
Canagliflozin—ORM1—liver—sarcoma	0.00102	0.0125	CbGeAlD
Canagliflozin—Rash erythematous—Epirubicin—sarcoma	0.00098	0.00794	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Vincristine—sarcoma	0.000947	0.00767	CcSEcCtD
Canagliflozin—ALB—testis—sarcoma	0.000944	0.0116	CbGeAlD
Canagliflozin—Rash pustular—Epirubicin—sarcoma	0.000941	0.00763	CcSEcCtD
Canagliflozin—Urinary tract disorder—Thiotepa—sarcoma	0.000925	0.00749	CcSEcCtD
Canagliflozin—Urethral disorder—Thiotepa—sarcoma	0.000918	0.00744	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—sarcoma	0.000907	0.00735	CcSEcCtD
Canagliflozin—ALB—liver—sarcoma	0.000892	0.0109	CbGeAlD
Canagliflozin—ABCC2—testis—sarcoma	0.000884	0.0108	CbGeAlD
Canagliflozin—Urinary tract infection—Mitoxantrone—sarcoma	0.000875	0.00709	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—sarcoma	0.000871	0.00706	CcSEcCtD
Canagliflozin—Angiopathy—Thiotepa—sarcoma	0.000849	0.00688	CcSEcCtD
Canagliflozin—ABCC2—liver—sarcoma	0.000836	0.0102	CbGeAlD
Canagliflozin—Urinary tract disorder—Vincristine—sarcoma	0.00082	0.00664	CcSEcCtD
Canagliflozin—CYP3A4—hematopoietic system—sarcoma	0.00082	0.01	CbGeAlD
Canagliflozin—Erythema—Thiotepa—sarcoma	0.000815	0.00661	CcSEcCtD
Canagliflozin—Malnutrition—Thiotepa—sarcoma	0.000815	0.00661	CcSEcCtD
Canagliflozin—Urethral disorder—Vincristine—sarcoma	0.000814	0.0066	CcSEcCtD
Canagliflozin—Nocturia—Epirubicin—sarcoma	0.000809	0.00656	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—sarcoma	0.000809	0.00656	CcSEcCtD
Canagliflozin—ORM1—lymph node—sarcoma	0.00078	0.00955	CbGeAlD
Canagliflozin—Angiopathy—Vincristine—sarcoma	0.000753	0.0061	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—sarcoma	0.000749	0.00607	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—sarcoma	0.000738	0.00598	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—sarcoma	0.000733	0.00594	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—sarcoma	0.000725	0.00587	CcSEcCtD
Canagliflozin—Vaginal infection—Epirubicin—sarcoma	0.000709	0.00574	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—sarcoma	0.000709	0.00574	CcSEcCtD
Canagliflozin—Convulsion—Thiotepa—sarcoma	0.000706	0.00572	CcSEcCtD
Canagliflozin—Erythema—Mitoxantrone—sarcoma	0.000704	0.0057	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000689	0.00558	CcSEcCtD
Canagliflozin—ALB—lymph node—sarcoma	0.000684	0.00837	CbGeAlD
Canagliflozin—Hyperkalaemia—Doxorubicin—sarcoma	0.000682	0.00553	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—sarcoma	0.000682	0.00553	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—sarcoma	0.000679	0.0055	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—sarcoma	0.000678	0.0055	CcSEcCtD
Canagliflozin—ABCB1—myometrium—sarcoma	0.000676	0.00827	CbGeAlD
Canagliflozin—Cystitis—Doxorubicin—sarcoma	0.000671	0.00544	CcSEcCtD
Canagliflozin—Urinary tract disorder—Etoposide—sarcoma	0.000664	0.00538	CcSEcCtD
Canagliflozin—Infection—Thiotepa—sarcoma	0.000661	0.00536	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—sarcoma	0.000659	0.00534	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—sarcoma	0.000656	0.00532	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—sarcoma	0.000656	0.00531	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—sarcoma	0.000656	0.00531	CcSEcCtD
Canagliflozin—Nervous system disorder—Thiotepa—sarcoma	0.000652	0.00529	CcSEcCtD
Canagliflozin—ABCB1—embryo—sarcoma	0.00065	0.00796	CbGeAlD
Canagliflozin—Skin disorder—Thiotepa—sarcoma	0.000646	0.00524	CcSEcCtD
Canagliflozin—ABCC2—lymph node—sarcoma	0.000641	0.00785	CbGeAlD
Canagliflozin—Rash maculo-papular—Doxorubicin—sarcoma	0.000631	0.00512	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—sarcoma	0.000628	0.00509	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—sarcoma	0.000626	0.00508	CcSEcCtD
Canagliflozin—Convulsion—Vincristine—sarcoma	0.000626	0.00507	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—sarcoma	0.000621	0.00503	CcSEcCtD
Canagliflozin—ABCB1—seminal vesicle—sarcoma	0.00061	0.00747	CbGeAlD
Canagliflozin—Angiopathy—Etoposide—sarcoma	0.00061	0.00494	CcSEcCtD
Canagliflozin—Convulsion—Mitoxantrone—sarcoma	0.00061	0.00494	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—sarcoma	0.00059	0.00478	CcSEcCtD
Canagliflozin—Infection—Vincristine—sarcoma	0.000586	0.00475	CcSEcCtD
Canagliflozin—ABCB1—hematopoietic system—sarcoma	0.00058	0.0071	CbGeAlD
Canagliflozin—Diabetes mellitus—Doxorubicin—sarcoma	0.00058	0.0047	CcSEcCtD
Canagliflozin—Nervous system disorder—Vincristine—sarcoma	0.000578	0.00469	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Thiotepa—sarcoma	0.000574	0.00465	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—sarcoma	0.000574	0.00465	CcSEcCtD
Canagliflozin—Fatigue—Thiotepa—sarcoma	0.000573	0.00465	CcSEcCtD
Canagliflozin—Infection—Mitoxantrone—sarcoma	0.000571	0.00462	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—sarcoma	0.000569	0.00461	CcSEcCtD
Canagliflozin—Constipation—Thiotepa—sarcoma	0.000569	0.00461	CcSEcCtD
Canagliflozin—Shock—Mitoxantrone—sarcoma	0.000565	0.00458	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—sarcoma	0.000558	0.00453	CcSEcCtD
Canagliflozin—Skin disorder—Mitoxantrone—sarcoma	0.000558	0.00452	CcSEcCtD
Canagliflozin—Hypotension—Vincristine—sarcoma	0.000551	0.00447	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—sarcoma	0.000546	0.00443	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Thiotepa—sarcoma	0.000544	0.00441	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—sarcoma	0.00054	0.00437	CcSEcCtD
Canagliflozin—Hypotension—Mitoxantrone—sarcoma	0.000537	0.00435	CcSEcCtD
Canagliflozin—Urticaria—Thiotepa—sarcoma	0.000528	0.00428	CcSEcCtD
Canagliflozin—Abdominal pain—Thiotepa—sarcoma	0.000526	0.00426	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—sarcoma	0.000522	0.00423	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—sarcoma	0.000517	0.00419	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—sarcoma	0.000515	0.00417	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—sarcoma	0.00051	0.00414	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vincristine—sarcoma	0.000509	0.00413	CcSEcCtD
Canagliflozin—Fatigue—Vincristine—sarcoma	0.000508	0.00412	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—sarcoma	0.000507	0.00411	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—sarcoma	0.000507	0.00411	CcSEcCtD
Canagliflozin—Constipation—Vincristine—sarcoma	0.000504	0.00409	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—sarcoma	0.000498	0.00403	CcSEcCtD
Canagliflozin—Fatigue—Mitoxantrone—sarcoma	0.000495	0.00401	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000495	0.00401	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—sarcoma	0.000492	0.00399	CcSEcCtD
Canagliflozin—Constipation—Mitoxantrone—sarcoma	0.000491	0.00398	CcSEcCtD
Canagliflozin—Hypersensitivity—Thiotepa—sarcoma	0.00049	0.00397	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—sarcoma	0.000486	0.00394	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vincristine—sarcoma	0.000482	0.00391	CcSEcCtD
Canagliflozin—Asthenia—Thiotepa—sarcoma	0.000477	0.00387	CcSEcCtD
Canagliflozin—Infection—Etoposide—sarcoma	0.000475	0.00385	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—sarcoma	0.000474	0.00384	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—sarcoma	0.000472	0.00383	CcSEcCtD
Canagliflozin—Pruritus—Thiotepa—sarcoma	0.000471	0.00381	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00047	0.00381	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—sarcoma	0.000469	0.0038	CcSEcCtD
Canagliflozin—Abdominal pain—Vincristine—sarcoma	0.000466	0.00378	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—sarcoma	0.000464	0.00376	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—sarcoma	0.000462	0.00374	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—sarcoma	0.00046	0.00373	CcSEcCtD
Canagliflozin—Urticaria—Mitoxantrone—sarcoma	0.000456	0.0037	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—sarcoma	0.000456	0.00369	CcSEcCtD
Canagliflozin—Abdominal pain—Mitoxantrone—sarcoma	0.000454	0.00368	CcSEcCtD
Canagliflozin—Hypotension—Etoposide—sarcoma	0.000446	0.00362	CcSEcCtD
Canagliflozin—Dizziness—Thiotepa—sarcoma	0.00044	0.00356	CcSEcCtD
Canagliflozin—ABCB1—uterus—sarcoma	0.000438	0.00537	CbGeAlD
Canagliflozin—Pollakiuria—Epirubicin—sarcoma	0.000435	0.00353	CcSEcCtD
Canagliflozin—Hypersensitivity—Vincristine—sarcoma	0.000435	0.00352	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—sarcoma	0.00043	0.00348	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—sarcoma	0.000427	0.00346	CcSEcCtD
Canagliflozin—CYP3A4—liver—sarcoma	0.000425	0.0052	CbGeAlD
Canagliflozin—Hypersensitivity—Mitoxantrone—sarcoma	0.000423	0.00343	CcSEcCtD
Canagliflozin—Asthenia—Vincristine—sarcoma	0.000423	0.00343	CcSEcCtD
Canagliflozin—Rash—Thiotepa—sarcoma	0.000419	0.0034	CcSEcCtD
Canagliflozin—Dermatitis—Thiotepa—sarcoma	0.000419	0.0034	CcSEcCtD
Canagliflozin—Rash—Dactinomycin—sarcoma	0.000416	0.00337	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—sarcoma	0.000412	0.00334	CcSEcCtD
Canagliflozin—Asthenia—Mitoxantrone—sarcoma	0.000412	0.00334	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—sarcoma	0.000412	0.00334	CcSEcCtD
Canagliflozin—Constipation—Etoposide—sarcoma	0.000409	0.00331	CcSEcCtD
Canagliflozin—ABCB1—lymphoid tissue—sarcoma	0.000408	0.005	CbGeAlD
Canagliflozin—Urinary tract infection—Epirubicin—sarcoma	0.000408	0.00331	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—sarcoma	0.000403	0.00326	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—sarcoma	0.000398	0.00322	CcSEcCtD
Canagliflozin—Nausea—Thiotepa—sarcoma	0.000395	0.0032	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—sarcoma	0.000392	0.00318	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—sarcoma	0.000391	0.00317	CcSEcCtD
Canagliflozin—Dizziness—Vincristine—sarcoma	0.00039	0.00316	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—sarcoma	0.00038	0.00308	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—sarcoma	0.000378	0.00306	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—sarcoma	0.000378	0.00306	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—sarcoma	0.000372	0.00302	CcSEcCtD
Canagliflozin—ABCB1—bone marrow—sarcoma	0.000372	0.00455	CbGeAlD
Canagliflozin—Rash—Vincristine—sarcoma	0.000372	0.00301	CcSEcCtD
Canagliflozin—Dermatitis—Vincristine—sarcoma	0.000372	0.00301	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—sarcoma	0.00037	0.00299	CcSEcCtD
Canagliflozin—Rash—Mitoxantrone—sarcoma	0.000362	0.00294	CcSEcCtD
Canagliflozin—Dermatitis—Mitoxantrone—sarcoma	0.000362	0.00293	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—sarcoma	0.000352	0.00285	CcSEcCtD
Canagliflozin—Nausea—Vincristine—sarcoma	0.00035	0.00284	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—sarcoma	0.000344	0.00279	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—sarcoma	0.000343	0.00278	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—sarcoma	0.000342	0.00277	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—sarcoma	0.000342	0.00277	CcSEcCtD
Canagliflozin—Nausea—Mitoxantrone—sarcoma	0.000341	0.00277	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—sarcoma	0.000338	0.00274	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—sarcoma	0.000328	0.00266	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—sarcoma	0.000328	0.00266	CcSEcCtD
Canagliflozin—ABCB1—testis—sarcoma	0.000318	0.00389	CbGeAlD
Canagliflozin—Angiopathy—Doxorubicin—sarcoma	0.000316	0.00256	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—sarcoma	0.000316	0.00256	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—sarcoma	0.000304	0.00246	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—sarcoma	0.000304	0.00246	CcSEcCtD
Canagliflozin—Rash—Etoposide—sarcoma	0.000301	0.00244	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—sarcoma	0.000301	0.00244	CcSEcCtD
Canagliflozin—ABCB1—liver—sarcoma	0.000301	0.00368	CbGeAlD
Canagliflozin—Syncope—Epirubicin—sarcoma	0.000294	0.00239	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—sarcoma	0.000288	0.00234	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—sarcoma	0.000284	0.0023	CcSEcCtD
Canagliflozin—Nausea—Etoposide—sarcoma	0.000284	0.0023	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000277	0.00225	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—sarcoma	0.000273	0.00221	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—sarcoma	0.000272	0.00221	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—sarcoma	0.000267	0.00216	CcSEcCtD
Canagliflozin—Infection—Epirubicin—sarcoma	0.000266	0.00216	CcSEcCtD
Canagliflozin—Shock—Epirubicin—sarcoma	0.000263	0.00214	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—sarcoma	0.000263	0.00213	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—sarcoma	0.000263	0.00213	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—sarcoma	0.00026	0.00211	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000257	0.00208	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—sarcoma	0.000253	0.00205	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—sarcoma	0.00025	0.00203	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—sarcoma	0.000246	0.002	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—sarcoma	0.000244	0.00198	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—sarcoma	0.000243	0.00197	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—sarcoma	0.000241	0.00195	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—sarcoma	0.000232	0.00188	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—sarcoma	0.000231	0.00187	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—sarcoma	0.000231	0.00187	CcSEcCtD
Canagliflozin—ABCB1—lymph node—sarcoma	0.00023	0.00282	CbGeAlD
Canagliflozin—Constipation—Epirubicin—sarcoma	0.000229	0.00186	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—sarcoma	0.000219	0.00177	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000214	0.00173	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—sarcoma	0.000214	0.00173	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—sarcoma	0.000213	0.00172	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—sarcoma	0.000212	0.00172	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—sarcoma	0.000212	0.00172	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—sarcoma	0.000203	0.00164	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—sarcoma	0.000197	0.0016	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—sarcoma	0.000197	0.0016	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—sarcoma	0.000196	0.00159	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—sarcoma	0.000192	0.00156	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—sarcoma	0.000189	0.00154	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—sarcoma	0.000183	0.00148	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—sarcoma	0.000178	0.00144	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—sarcoma	0.000177	0.00144	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—sarcoma	0.000175	0.00142	CcSEcCtD
Canagliflozin—Rash—Epirubicin—sarcoma	0.000169	0.00137	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—sarcoma	0.000169	0.00137	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—sarcoma	0.000164	0.00133	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—sarcoma	0.000159	0.00129	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—sarcoma	0.000156	0.00127	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—sarcoma	0.000156	0.00127	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—sarcoma	0.000147	0.00119	CcSEcCtD
